genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it will release its financial results for the year ended 30 June 2020 on Tuesday 17 November 2020.
Genedrive PLC (GDR.L) Notice of Results
Genedrive PLC (GDR.L) Point-of-Care solution to detect SARS-CoV-2 virus
Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it has completed the assay design for the Company’s Point-of-Care (“POC”) solution for COVID-19 testing and is now generating
Genedrive PLC (GDR.L) Verification with Beckman Coulter Life Sciences
Genedrive® 96 SARS-CoV-2 Kit verified with Beckman Coulter Life Sciences RNA extraction chemistry
Genedrive PLC (GDR.L) Collaboration to automate COVID-19 PCR testing
Beckman Coulter collaboration to automate high throughput SARS-CoV-2 PCR testing
Genedrive PLC (GDR.L) Investor presentation
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, is pleased to announce that David Budd, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by
David Budd, Chief Executive Officer of Genedrive PLC (GDR.L) Podcast
Share Talk caught up with Manchester-based company Genedrive PLC and spoke with David Budd, CEO about the company recent announcement with the development of two coronavirus tests, one for central
Novacyt S.A. (LON:NCYT) Launch of novel coronavirus test
Graham Mullis, Chief Executive Officer of Novacyt commented. Over the last few days, we have seen significant early demand for our genesig® 2019-nCoV test from over 10 countries.
